US Patent

US10512620 — Method of initiating and escalating sotalol hydrochloride dosing

Method of Use · Assigned to Altathera Pharmaceuticals LLC · Expires 2038-08-14 · 12y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof using rapid intravenous introduction of sotalol hydrochloride.

USPTO Abstract

This disclosure provides method of safely and efficaciously treating or preventing atrial fibrillation, atrial flutter, or a combination thereof via rapid intravenous introduction of sotalol hydrochloride to a subject in need thereof.

Drugs covered by this patent

sotalol-hydrochloride (SOTALOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2769`	—	sotalol-hydrochloride

Patent Metadata

Patent number: US10512620
Jurisdiction: US
Classification: Method of Use
Expires: 2038-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Altathera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.